Abstract
Purpose
The present study was undertaken to test circulating autoantibody to ATP-binding cassette C3 (ABCC3) transporter in order to confirm whether anti-ABCC3 antibody could serve as a biomarker for early diagnosis of lung cancer.
Methods
This study recruited 275 patients (178 males and 97 females) with non-small cell lung cancer (either squamous carcinoma or adenocarcinoma) and 226 control subjects (134 males and 92 females) well matched in age and smoking history. Anti-ABCC3 IgA and IgG were determined using an enzyme-linked immunosorbent assay (ELISA) approach that was developed in house with the human leukocyte antigen class II (HLA-II) restricted antigens.
Results
Mann–Whitney U test showed that the IgG antibody level was significantly higher in female patients with adenocarcinoma than female controls (Z = −4.34, P < 0.001) and that the IgA antibody level was significantly higher in male patients with squamous carcinoma than male controls (Z = −3.12, P = 0.002). Pearson’s Chi-square (χ2) test showed that female patients with adenocarcinoma had a significantly higher positive rate for IgG autoantibody than female controls (χ 2 = 8.73, P = 0.003). The ELISA sensitivity against a specificity of >95 % was 18.1 % for IgG assay in female patients and 18.0 % for IgA assay in male patients. The inter-assay deviation was 10.6 % for IgG assay and 14.5 % for IgA assay.
Conclusions
Circulating autoantibodies to ABCC3 transporter may be a potential biomarker that can be added to a panel of existing biomarkers for early diagnosis and prognosis of lung cancer although the gender differences should be taken into account.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, Marth C (2000) Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res 20(1B): 569–572
Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D (2010) p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 19(3):859–868
Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22:383–389
Calcagno AM, Ambudkar SV (2010) Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 596:77–93
Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873
Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA, Maddison P, Robertson JF (2011) Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 17:1474–1480
Gatti L, Cossa G, Beretta GL, Zaffaroni N, Perego P (2011) Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 18:4237–4249
Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML (2006) Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 24:762–768
Järås K, Anderson K (2011) Autoantibodies in cancer: prognostic biomarkers and immune activation. Expert Rev Proteomics 8:577–589
Kobold S, Lütkens T, Cao Y, Bokemeyer C, Atanackovic D (2010) Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol 71:643–651
Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF (2011) EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) 4:1126–1134
Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang J-Y (2011) Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev 10:331–335
Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C, Corre E, Lapusan S, Lallemand JY, Marie JP, Jacquet E, Legrand O (2011) ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 96:1293–1301
Mayerhofer K, Tempfer C, Kucera E, Hefler L, Zeisler H, Kainz C, Zeillinger R, Sliutz G (1999) Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 19(1B): 875–878
Murray A, Chapman CJ, Healey G, Peek LJ, Parsons G, Baldwin D, Barnes A, Sewell HF, Fritsche HA, Robertson JF (2010) Technical validation of an autoantibody test for lung cancer. Ann Oncol 21:1687–1693
Piura E, Piura B (2010) Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol 2010: 264926 (Epub)
Piura E, Piura B (2011) Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol 2011: 982425 (Epub)
Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58:1535–1544
Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, Mayer B (2010) Concept and application of a computational vaccinology workflow. Immunome Res 6(Suppl 2):S7
Tan HT, Low J, Lim SG, Chung MC (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880–6904
Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B (2010) Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinf 11: 568 (Epub)
Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA (2006) Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1:513–519
Acknowledgments
We thank patients and healthy volunteers for your participation in this study. This work was supported by the grants from the Science and Technology Bureau of Jilin Province, Changchun, China (M2111603429) and from the Development and Reform Commission of Jilin Province, Changchun, China (D5111323429).
Conflict of interest
All the authors declared that they had no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, L., Liu, N., Liu, B. et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?. J Cancer Res Clin Oncol 138, 1737–1742 (2012). https://doi.org/10.1007/s00432-012-1260-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1260-9